Sun Pharma Advanced Research Company Ltd. (SPARC) announced that the United States Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Priority Review Voucher (PRV) associated with the approval of Sezaby. 

A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases that can be redeemed to receive a priority review for a subsequent, separate drug application. 

"Receiving this Priority Review Voucher is a significant milestone for SPARC and a testament to our commitment to addressing the urgent, unmet needs of patients," said Anil Raghavan, CEO of SPARC. "This award not only recognizes the therapeutic value of Sezaby® but also provides SPARC with additional strategic flexibility to accelerate our pipeline development to bring more therapies to patients faster."